Market research
OPTN OptiNose
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 97M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- -0.89
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US68404V1008
- Market cap
- 97M
- P/E ratio
- Not available
- Analyst target
- 21
- Dividend yield
- Not available
- Beta
- -0.89
About
About OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OPTN discussion.
5 years, 4 months ago
OptiNose, Inc is currently in a long term downtrend where the price is trading 24.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
OptiNose, Inc's total revenue rose by 47.5% to $16M since the same quarter in the previous year.
Its net income has increased by 4.5% to $-24M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.9% to $-19M since the same quarter in the previous year.
Based on the above factors, OptiNose, Inc gets an overall score of 3/5.